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Disease Management Association of America
Washington, DC
This roundtable discussion emanates from the presentations given and issues
raised at the 2006 Disease Management Colloquium, which was held May 10–12,
2006 in Philadelphia, Pennsylvania.
David Nash, MD, MBA: Our goal today is to
provide an after-action report of the key themes
and take-home messages from the Disease
Management Colloquium to the readers of Dis-
ease Management.
Let’s begin with Rob Greene. Rob, you were
a presenter in the Pay-for-Performance and
Other Incentives in Disease Management Pro-
grams track. Will you summarize the main
messages from your presentation on the work
of RIPA (Rochester Individual Practice Associ-
ation) for us?
Robert A. Greene, MD: Sure. RIPA is a physi-
cian-led individual practice association with a
pay-for-performance program. We tracked and
reported on individual physician performance
and we were involved with the Robert Wood
Johnson Rewarding Results grant, so we used
diabetes, coronary artery disease, and asthma
as our chronic diseases.
There are two take-home lessons that we
learned over these last few years that I will
summarize for you. The first lesson is the im-
portance of process in dealing with the physi-
cian. It took a great deal of very active, well-
thought-out, relationship-centered work to get
physician engagement. The second lesson is to
give the physician specific action items.
In my presentation, I listed eight lessons for
engaging physicians and making a successful
program. For example, establishing goals and
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values, and treating physicians with respect.
But what it comes down to is working with
physicians through their anger and denial and
issues with having grades. You have to respect
that. We found that the physicians who made
it through that process and moved on to ac-
ceptance actually were the ones who did bet-
ter in our program. The key is using a rela-
tionship-centered process to help physicians
get through their anger and denial and get to
the point where they’ll work with you.
We met with doctors from our family prac-
tice group and found that the ones who did
well in this program indicated that they had
taken the disease registries we provided and
used the information. The doctors who didn’t
do well in the program were still angry; they
hadn’t worked through that. That’s one lesson.
The second lesson is providing doctors with
specific action items. We sent out patient-spe-
cific registries four times a year that gave doc-
tors issues to work on.
A third lesson, which I touched on at the con-
ference, was that the people who accepted the
program also made system changes. Some-
times they were very minor, but they were low
cost system changes. For example, the practice
manager for one cardiology group took all the
CAD (coronary artery disease) patients that we
had sent them on CD, and used the informa-
tion to make a chart extraction form. Their
medical records people just went through those
patients’ charts and that group received a 4.0—
a perfect score—in their first time out on the
CAD measure.
So, there actually were three main points.
Dr. Nash: Follow-up question to you, Rob.
What are the future plans for the pay-for-per-
formance program at RIPA?
Dr. Greene: First, we would like to move to a
Web-based system. We started out with many
doctors not being Web enabled so we’ve had
to work with a paper-based system.
Second, we want to connect our registries
with disease management. I’d love to see the
registries populated with predictive modeling
numbers. We could identify the diabetics who
are a five instead of a one in severity. Their
physicians would have that information. We
may pay those physicians whose patients have
higher disease severity more for performance
improvement.
Third, we’re using a new analytic tool to find
specific cost drivers and turning those into
overuse quality measures. In diabetes care and
asthma care, you’re always trying to do more—
not enough hemoglobin A1C’s are done, not
enough inhaled steroids. In some conditions,
too much is done. For example, there’s too
much antibiotic use in treating sinusitis. When
you can find a quality measure like that you
can save costs and improve care right off the
bat. Those are our future directions.
Dr. Nash: Great. Thank you, Rob. Now let’s
hear from Nancy McCall. Nancy, you were a
key moderator at the meeting, and your track
was concerned with the Medicare Health Sup-
port Program. Please share with us the princi-
ple messages you took away from the panel
discussion and then we can talk about the fu-
ture of Medicare health support. What did you
hear from the field about how it’s going?
Nancy McCall, ScD: I think our track was a lit-
tle bit broader than Medicare Health Support.
We started with the American College of Car-
diology representative talking about Medicare
Health Support, what their role has been to
date, and their interest in being involved in the
evaluation.
It was clear that they are interested in dis-
ease management and in helping to identify ev-
idence-based metrics that can be used to mon-
itor the quality of care provided to Medicare
beneficiaries with congestive heart failure and
diabetes. They believe that diabetes is clearly
within their purview because they’ve found
that there are very few diabetics who do not
also have some sort of coronary artery disease.
They clearly think that the Medicare Health
Support efforts will definitely benefit Medicare
beneficiaries by focusing on managing hyper-
tension and using appropriate medications.
The same is true for diabetes, where the bene-
fit will come from focusing on hemoglobin A1c
management. They expect that the most im-
portant short-term outcomes will be to reduce
emergency room visits and reduce hospitaliza-
tions by stabilizing people.
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The track also included Medicaid experience
with disease management. This is where the
audience became extremely engaged. There
were presentations from Colorado, Rhode Is-
land, and Florida, and people were really in-
terested in the nuts and bolts of how to engage
the Medicaid population because it is an ex-
tremely challenging population. A large por-
tion of the attendees appeared to be from Med-
icaid programs. They wanted to hear from the
different programs about such issues as creat-
ing culturally and linguistically appropriate
material; not making any assumptions about
the language skills of a Medicaid population;
different mechanisms to reach out to the pop-
ulation, such as community workers as op-
posed to call centers; and which models might
work better for different populations. There
was a lot of interest in what’s happening in the
Medicaid programs.
Dr. Nash: Nancy, while you have the floor,
would you speak a little bit about what you see
as some of the challenges to the Medicare
Health Support Program moving forward?
Dr. McCall: In my personal opinion, one of the
issues is that this population is quite sick, and
there will be a very high death rate in this pop-
ulation. The question becomes whether the
Medicare Health Support Program is a viable
business model. As the pilot goes forward,
what will be the rules for increasing or re-
freshing the populations, or what will CMS
(Centers for Medicare and Medicaid Services)
do to allow additional beneficiaries to be added
in? The programs have all “ramped up” and,
as the population dies off, the question be-
comes how viable is that model.
Dr. Nash: Thank you, Nancy. That was great.
Ron Loeppke, let’s move on to you. You were
a key participant in the Innovative Disease
Management Products and Services track.
Please summarize for us some of the take-home
messages that you presented at the meeting.
Ronald R. Loeppke, MD, MPH: What I no-
ticed, not only in the innovative track that I par-
ticipated in but throughout other sessions that
I was able to attend, is that a system transfor-
mation is beginning to occur around the fun-
damental premise that it’s more about pop-
ulation health management—improving the
health of populations—as well as the quality of
the care.
Those two fundamental pillars of prevention
and evidence-based medicine quality improve-
ment for those who already have a disease or
condition seem to be the underlying initiative
that’s occurring—and occurring in several
ways.
First, by aligning incentives among the key
stakeholders, as we’ve already heard in some
of the discussion about pay-for-performance
for providers. Providers are one of the key
stakeholders who are more actively engaged in
quality improvement on the supply side. Sec-
ond, on the demand side of health care, con-
sumer or patient engagement and incentives
can be much more aligned with the initiatives
of the physicians. Trying to improve the qual-
ity of care for those who have chronic condi-
tions, and trying to engage those who may not
have a specific medical condition but who have
definite high health risks and need to more ac-
tively participate in lowering those risks and
improving their health.
Essentially, it’s clearly emerging that good
health is good business—and that good medi-
cine is good business.
The value proposition that is beginning to
emerge involves defining the business value of
health. This goes beyond the traditional met-
rics of looking at the type of impact disease
management initiatives have on reducing uti-
lization or reducing medical and pharmacy
costs. We need to look into what the employer
community is asking for; how to help them get
their arms around the health-related produc-
tivity losses they face due to absenteeism from
work, as well as the impact of presenteeism,
where workers are present but not as produc-
tive because their medical conditions are not
well managed, or their health risks are out of
control.
I think that broader value proposition of
health and productivity types of metrics is an
important one. One study we were able to talk
about in my presentation showed that across
the United States, on average, for every one
dollar of direct medical/pharmacy costs em-
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ployers pay, they’re paying approximately
two-to-three dollars for health-related produc-
tivity losses due to absenteeism, presenteeism,
and short- and long-term disability.
Dr. Nash: Ron, could you tell us what you feel
are some of the most innovative disease man-
agement products or services coming down the
pike?
Dr. Loeppke: I think what’s interesting is the
huge role that technology is continuing to play
as more user-friendly solutions are coming into
play for the consumer, as well as for the provider.
Some innovation is largely focused on data-
driven solutions, allowing you to look at a lot
of the different data components for a popula-
tion, or even for an individual, and then be able
to find a blueprint for action emerging from
that analysis. The importance of innovation in
the use of data and technology in that space, I
think, continues to be demonstrated.
But just as important, though, is that inte-
grated approaches now are becoming much
more the norm. Instead of condition-specific
disease management alone, there now is the
ability to orchestrate evidence-based medicine
approaches for individual conditions across a
whole population—in terms of how to prevent
those conditions from developing in the first
place—and being able to touch the whole pop-
ulation with some health management types of
initiatives.
Integration is also key with new innovation.
I think the integration requires this technology
and data management, and essentially distill-
ing data into information. So, information is go-
ing to drive a lot of innovation.
Dr. Nash: Great. Thank you, Ron. Tracey Moor-
head, you had the dubious distinction of try-
ing to moderate all of the CEOs, and you did
a great job. Will you tell us some of the main
messages that you took away from the CEO
panel at the end of the conference?
Tracey Moorhead: I would be glad to try, and
inasmuch as anyone can moderate five CEO’s
I worked hard at it.
I asked the panelists to identify either a trend
or a challenge for disease management that
they see coming up in the future, and a couple
of scenarios were presented. I thought that the
panel was a great synopsis of all of the other
excellent presentations that had occurred in the
previous two and a half days.
Chris Selecky of Life Masters talked about
the importance and the potential impact of the
Medicare Health Support Program on disease
management as a concept and as an industry.
She talked about the potential negative impact
on the industry if the pilot programs are not
successful, but said that, in all likelihood, they
would be successful and would show an im-
provement in the care of the beneficiaries who
are participating.
She talked about the opportunity that these
pilot programs, as opposed to demonstration
projects, present to the industry and outlined—
very well, I thought—the work that the indus-
try did to assist both Congress and CMS in de-
veloping them. She spoke briefly about the
work that DMAA is doing to help CMS con-
sider issues that need to be addressed as they
develop Phase II of the Medicare Health Sup-
port Program, in which the existing pilots will
be added to through a new round of contract-
ing to provide similar services to additional
Medicare beneficiaries.
Jim Pope from Healthways spoke very elo-
quently on the importance of establishing the
proof of return on investment, or return of
value, on disease management programs. He
spoke generally about the efforts that have
been under way for several years to ascertain
the true impact of these programs on popula-
tions and the impact on the bottom line of the
purchasers of these programs. He also spoke
specifically about the DMAA’s ongoing efforts
to establish a methodology to measure the im-
pact of disease management programs.
Dr. Fabius from I-trax spoke about the im-
portance of implementing trusted physicians
and the clinical setting in the workplace, and
the integration of disease and care manage-
ment programs directly in the workplace in the
employer market. Knowing that this is a po-
tential trend and a model for future care de-
livery, I thought his remarks were very in-
triguing—particularly his anecdote of the
physician who simply couldn’t walk down the
hallway without being greeted and spoken to
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by employees in the company in which he was
working, and the impact on health and pro-
ductivity that the physical location of the clin-
ician in the workplace can potentially have for
those employers who choose to adopt this
model.
I thought Dr. Bennett from Health Dialog re-
ally summed up quite a few of the presenta-
tions of the previous days by talking about the
critical mass that he believes exists currently,
pointing out that disease management has re-
ally proven itself as a clinical concept. There is
a growing interest in disease management
among large and mid-sized employers, health
plans of all sizes, the federal government and
state Medicaid programs, and now even inter-
nationally. There is interest in disease man-
agement programs, the implementation of 
programs, and the adoption of disease man-
agement. Having proven disease management
as a concept really showcases and highlights
the opportunities that exist to move forward.
Dr. Rizk from McKesson spoke about the im-
pact of technology on disease management and
the need for technological support services to
assist in the provision of disease management
applications.
I thought that the brief discussion we had re-
garding the definition of disease management
that had been drafted by the DMAA and ac-
cepted widely over the last couple of years also
was quite insightful. We highlighted some key
phrases in the definition that addressed some of
the issues that had been discussed over the pre-
vious couple of days, particularly the first part
of the definition that notes that disease manage-
ment supports the physician, emphasizes evi-
dence-based practice guidelines and patient em-
powerment strategies, and evaluates outcomes.
I asked the panelists to comment on whether
they found the definition to continue to be rel-
evant to the disease management industry.
There was an indication that, while the defini-
tion is still widely relevant, we may need to
take a fresh look at it to make sure that we are
supporting the physician with the proper inte-
gration of data-sharing systems, and integra-
tion of data into the physician’s practice model.
There also was a concern that perhaps we need
to reinforce the population-based approach to
disease management.
Finally, I think there was widespread agree-
ment that the phrase itself, disease manage-
ment, may need to be reconsidered both within
the definition and as the name of the organi-
zation.
Dr. Nash: Great summary, Tracey. Thank you
very much. Now, here is the final question for
today. Will each of you share your perspective
on the one-to-two main challenges for wide-
spread adoption of disease management tech-
niques in the future?
Tracey, may I start with you? I’m sure you
think about this every day in your role as ex-
ecutive director of DMMA. What are the one
or two main challenges that you see moving
forward?
Ms. Moorhead: I see establishing a consensus
methodology for evaluating the financial im-
pact of disease management programs as one
of the key challenges and, frankly, opportuni-
ties presented to the industry at this point.
We have outlined a process through which
we will develop a methodology, inviting all
stakeholders in the healthcare and disease
management industry to participate with us,
and we’re very hopeful that we will be able to
resolve this continuing conundrum.
The second most important challenge facing
the industry is the relationship with physicians.
We are working very hard to demonstrate the
support and assistance that disease manage-
ment programs certainly can provide to the
physician-led healthcare team.
Dr. Nash: Great, Tracey. Thank you. Ron
Loeppke—two major challenges to disease
management moving forward?
Dr. Loeppke: I think that the issue of the met-
rics of looking at the impact of disease man-
agement continues to be a challenge. The
sooner we can broaden the metrics to go be-
yond the traditional medical and pharmacy
costs and utilization components and into
broader health and productivity metrics, the
better. This is an opportunity for the industry
and one that’s relevant for the employer com-
munity, who want to buy value from disease
management initiatives.
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Once those metrics are broadened, I think
that disease management is going to redefine
itself. As was mentioned earlier by others, it
will go beyond just managing the chronic con-
ditions of a segment of the population—the
10%–15% of people—and more into working
with 100% of the population, helping to iden-
tify and prevent those conditions and to get the
business value for the health delivered.
The second challenge will center on the data
and the actual technological limitations that are
out there today for standardization and trans-
fer of appropriate data for those measurements.
It’s going to require a whole new way to be able
to get eligibility types of data “locked down”
in order to look at the different return on in-
vestment metrics. Because of that, the industry
has an opportunity to move into examining
how the clinical transactions with both the
physician and the patient or consumer can re-
ally be leveraged, rather than focusing on the
financial transactions from such issues as ben-
efit redesign or co-pay deductible distribution.
Dr. Nash: Thank you, Ron. And now to you,
Nancy, for the wrap-up. What are two major
challenges for disease management moving
forward?
Dr. McCall: One challenge is how to engage
consumers more actively at earlier stages of
their diseases in order to prevent serious de-
bilitating disease from occurring. There is
much focus on how providers are doing with
regard to making sure that their patients have
certain metrics done, and guideline-concor-
dant care, but I don’t see a similar parallel ef-
fort to find ways of holding consumers
equally accountable for their wellness. I think
that how to get consumers motivated to do a
better job at early intervention and preventing
serious disease from developing is a chal-
lenge.
A second area has to do with the very chron-
ically ill, like the older chronically ill who have
many comorbid conditions. How do we mea-
sure health and improvement of health, and
what realistic improvements should we be
looking for in those people affected by 15 or
more concurrent diseases? Figuring out what
is an appropriate measure of overall improve-
ment for very seriously ill people is a real chal-
lenge.
Dr. Nash: Outstanding. Well, in closing, let me
thank Mary Ann Liebert for the support for this
conference call. Thank you also to Nancy Mc-
Call, Robert Greene, Ron Loeppke, and Tracey
Moorhead for joining us. I really appreciate you
taking time from your busy schedules, and
thanks again for your help during the Disease
Management Colloquium.
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